PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31835640-0	2019	Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	118-132	
35146812-0	2022	In vivo electrophysiological study of the targeting of 5-HT3 receptor-expressing cortical interneurons by the multimodal antidepressant, vortioxetine.	Vortioxetine	137-149	5-hydroxytryptamine receptor 3A	Rattus norvegicus	55-69	
35146812-1	2022	The antidepressant vortioxetine has high affinity for the ionotropic 5-HT3 receptor (5-HT3 R) as well as other targets including the 5-HT transporter.	Vortioxetine	19-31	5-hydroxytryptamine receptor 3A	Rattus norvegicus	69-83	
35146812-1	2022	The antidepressant vortioxetine has high affinity for the ionotropic 5-HT3 receptor (5-HT3 R) as well as other targets including the 5-HT transporter.	Vortioxetine	19-31	5-hydroxytryptamine receptor 3A	Rattus norvegicus	85-92	
35146812-3	2022	Thus, vortioxetine purportedly inhibits cortical 5-HT3 R-expressing interneurons (5-HT3 R-INs) to disinhibit excitatory pyramidal neurons.	Vortioxetine	6-18	5-hydroxytryptamine receptor 3A	Rattus norvegicus	49-56	
35146812-3	2022	Thus, vortioxetine purportedly inhibits cortical 5-HT3 R-expressing interneurons (5-HT3 R-INs) to disinhibit excitatory pyramidal neurons.	Vortioxetine	6-18	5-hydroxytryptamine receptor 3A	Rattus norvegicus	82-89	
35146812-4	2022	The current study determined for the first time, the effect of vortioxetine on the in vivo firing of putative 5-HT3 R-INs whilst simultaneously recording pyramidal neuron activity using cortical slow-wave oscillations as a readout.	Vortioxetine	63-75	5-hydroxytryptamine receptor 3A	Rattus norvegicus	110-117	
35146812-8	2022	Vortioxetine inhibited the short-latency DRN-evoked excitation of 5-HT3 R-INs and simultaneously decreased cortical slow wave oscillations, indicative of pyramidal neuron activation.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	66-73	
35146812-12	2022	Overall, the current findings suggest that vortioxetine simultaneously inhibits (DRN-evoked) 5-HT3 R-INs and excites pyramidal neurons, thereby changing the excitatory:inhibitory balance in cortex.	Vortioxetine	43-55	5-hydroxytryptamine receptor 3A	Rattus norvegicus	93-100	
31835640-8	2019	These demonstrations, the desensitization of 5-HT1AR with the inhibition of 5-HT3R (without 5-HT3R desensitization), at least partially, contribute to the multimodal antidepressant action of vortioxetine in rats.	Vortioxetine	191-203	5-hydroxytryptamine receptor 3A	Rattus norvegicus	76-82	
29274875-0	2018	The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices.	Vortioxetine	30-42	5-hydroxytryptamine receptor 3A	Rattus norvegicus	97-111	
29274875-8	2018	Finally, in 5-HT3 receptor-expressing GABAergic interneurons from the CA1 stratum radiatum, vortioxetine and ondansetron blocked depolarizations induced by superfusion of either 5-HT or the 5-HT3 receptor agonist mCPBG.	Vortioxetine	92-104	5-hydroxytryptamine receptor 3A	Rattus norvegicus	12-26	
29274875-8	2018	Finally, in 5-HT3 receptor-expressing GABAergic interneurons from the CA1 stratum radiatum, vortioxetine and ondansetron blocked depolarizations induced by superfusion of either 5-HT or the 5-HT3 receptor agonist mCPBG.	Vortioxetine	92-104	5-hydroxytryptamine receptor 3A	Rattus norvegicus	190-204	
29274875-9	2018	Taken together, these data add to a growing literature supporting the idea that vortioxetine may inhibit GABAergic neurotransmission in some brain regions via a 5-HT3 receptor antagonism-dependent mechanism and thereby disinhibit pyramidal neurons and enhance glutamatergic signaling.	Vortioxetine	80-92	5-hydroxytryptamine receptor 3A	Rattus norvegicus	161-175	
23916504-0	2014	Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	170-184	
25524057-10	2015	In summary, vortioxetine prevented the effect of stress on hippocampal LTP, increased rapidly hippocampal cell proliferation and enhanced short-term episodic memory, via, at least in part, its 5-HT3 receptor antagonism.	Vortioxetine	12-24	5-hydroxytryptamine receptor 3A	Rattus norvegicus	193-207	
27106166-1	2016	The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor.	Vortioxetine	19-31	5-hydroxytryptamine receptor 3A	Rattus norvegicus	37-44	
27106166-4	2016	Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade.	Vortioxetine	116-128	5-hydroxytryptamine receptor 3A	Rattus norvegicus	28-35	
27106166-4	2016	Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade.	Vortioxetine	116-128	5-hydroxytryptamine receptor 3A	Rattus norvegicus	204-211	
26174134-11	2015	The 5-HT3 receptor antagonist ondansetron significantly reduced paroxetine"s acute effects on ROL, while the 5-HT3 receptor agonist SR57227A significantly increased vortioxetine"s acute effect on ROL.	Vortioxetine	165-177	5-hydroxytryptamine receptor 3A	Rattus norvegicus	109-123	
25122043-4	2014	Vortioxetine was found to prevent the 5-HT-induced increase in inhibitory post-synaptic potentials recorded from CA1 pyramidal cells, most likely by 5-HT3 receptor antagonism.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	149-163	
23916504-8	2014	Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	189-203	
23916504-8	2014	Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Rattus norvegicus	124-138	
23089374-0	2013	The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.	Vortioxetine	69-81	5-hydroxytryptamine receptor 3A	Rattus norvegicus	91-107	
23089374-14	2013	This is at least partly due to 5-HT(3) receptor antagonism of vortioxetine in association with its reduced SERT occupancy.	Vortioxetine	62-74	5-hydroxytryptamine receptor 3A	Rattus norvegicus	31-47